News

ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...
Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...
Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...
UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...
Among the guideline’s recommendations is the use of local low-dose vaginal estrogen as first-line therapy for GSM. The recent release of the “Genitourinary Syndrome of Menopause: AUA/SUFU [Society of ...
The relationship between clinical trial results and real-world experience with enzalutamide and darolutamide shows important patterns: The alignment between trial data and clinical experience supports ...
John Michael DiBianco, MD, discusses findings from the BLUES trial. A recent study evaluated silicone vs polyurethane stents found that the primary outcome of pain intensity and interference at 7 to ...
Investigators found that benefits of treatments that are observed in trials also appear in the real world. A recent study examined the relationship between randomized controlled trials and real-world ...
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation. Welcome back to Pearls & Perspectives! In this episode of Pearls & ...
Merrill discusses the evolving non–muscle invasive bladder cancer treatment space. Expanded access programs (EAPs), such as a recently FDA-authorized EAP in which ImmunityBio is partnering with the ...
Please share your concluding thoughts about the recent progress and future outlook of NMIBC.